Your browser doesn't support javascript.
loading
Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects.
Kozin, S A; Barykin, E P; Mitkevich, V A; Makarov, A A.
Afiliación
  • Kozin SA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
  • Barykin EP; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
  • Mitkevich VA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia. mitkevich@gmail.com.
  • Makarov AA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia. aamakarov@eimb.ru.
Biochemistry (Mosc) ; 83(9): 1057-1067, 2018 Sep.
Article en En | MEDLINE | ID: mdl-30472944
Drug development for the treatment of Alzheimer's disease (AD) has been for a long time focused on agents that were expected to support endogenous ß-amyloid (Aß) in a monomeric state and destroy soluble Aß oligomers and insoluble Aß aggregates. However, this strategy has failed over the last 20 years and was eventually abandoned. In this review, we propose a new approach to the anti-amyloid AD therapy based on the latest achievements in understanding molecular causes of cerebral amyloidosis in AD animal models.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos beta-Amiloides / Enfermedad de Alzheimer / Anticuerpos Monoclonales Límite: Animals / Humans Idioma: En Revista: Biochemistry (Mosc) Año: 2018 Tipo del documento: Article País de afiliación: Rusia Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos beta-Amiloides / Enfermedad de Alzheimer / Anticuerpos Monoclonales Límite: Animals / Humans Idioma: En Revista: Biochemistry (Mosc) Año: 2018 Tipo del documento: Article País de afiliación: Rusia Pais de publicación: Estados Unidos